TP53 and breast carcinoma: The study revealed that polyarginine and polyornithine significantly inhibit p53 mutant peptide aggregation in vitro and inhibit the growth of p53 mutant (R248Q) lung cancer cells H719 and p53 mutant (R175H) breast cancer cells SK-BR-3.